Erlotinib in first-line treatment of 70-years old patient with pulmonary adenocarcinoma

Abstract

Lung cancer is the most frequently cancer in men and the third most frequently type of cancer in women after breast and colon cancer. Lung cancer is the main cause of cancer-related deaths in men and in women too. The majority of patients is diagnosed with advanced stage of disease and the possibility of treatment is limited for palliative or symptomatic care. The introduction targeted molecular therapy in selected groups of patients in stage III and IV with non-small-cell lung cancer (NSCLC) and with activating EGFR gene mutation significantly improve progression free survival (PFS) and quality of life. The tolerance of therapy with tyrosine kinase inhibitors (TKI) is good. Here, a case of 70-years old men with NSCLC (adenocarcinoma) presented classical example qualification, course and tolerance of treatment in therapy with erlotinib.